Immunogenic cell death in cancer therapy
- PMID: 23157435
- DOI: 10.1146/annurev-immunol-032712-100008
Immunogenic cell death in cancer therapy
Abstract
Depending on the initiating stimulus, cancer cell death can be immunogenic or nonimmunogenic. Immunogenic cell death (ICD) involves changes in the composition of the cell surface as well as the release of soluble mediators, occurring in a defined temporal sequence. Such signals operate on a series of receptors expressed by dendritic cells to stimulate the presentation of tumor antigens to T cells. We postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies. Hence, suboptimal regimens (failing to induce ICD), selective alterations in cancer cells (preventing the emission of immunogenic signals during ICD), or defects in immune effectors (abolishing the perception of ICD by the immune system) can all contribute to therapeutic failure. We surmise that ICD and its subversion by pathogens also play major roles in antiviral immune responses.
Similar articles
-
Immunogenic cancer cell death: a key-lock paradigm.Curr Opin Immunol. 2008 Oct;20(5):504-11. doi: 10.1016/j.coi.2008.05.007. Epub 2008 Jun 23. Curr Opin Immunol. 2008. PMID: 18573340 Review.
-
Molecular characteristics of immunogenic cancer cell death.Cell Death Differ. 2008 Jan;15(1):3-12. doi: 10.1038/sj.cdd.4402269. Epub 2007 Nov 16. Cell Death Differ. 2008. PMID: 18007663 Review.
-
Inducers of immunogenic cancer cell death.Cytokine Growth Factor Rev. 2013 Aug;24(4):319-33. doi: 10.1016/j.cytogfr.2013.01.005. Epub 2013 Feb 5. Cytokine Growth Factor Rev. 2013. PMID: 23391812 Review.
-
Human tumor cells killed by anthracyclines induce a tumor-specific immune response.Cancer Res. 2011 Jul 15;71(14):4821-33. doi: 10.1158/0008-5472.CAN-11-0950. Epub 2011 May 20. Cancer Res. 2011. PMID: 21602432
-
Immunogenic cell death modalities and their impact on cancer treatment.Apoptosis. 2009 Apr;14(4):364-75. doi: 10.1007/s10495-008-0303-9. Apoptosis. 2009. PMID: 19145485 Review.
Cited by
-
ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death.Theranostics. 2020 Sep 14;10(24):11197-11214. doi: 10.7150/thno.44920. eCollection 2020. Theranostics. 2020. PMID: 33042278 Free PMC article.
-
Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.PLoS One. 2015 Jun 22;10(6):e0130249. doi: 10.1371/journal.pone.0130249. eCollection 2015. PLoS One. 2015. PMID: 26098691 Free PMC article.
-
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.J Immunother Cancer. 2020 Jul;8(2):e000999. doi: 10.1136/jitc-2020-000999. J Immunother Cancer. 2020. PMID: 32690772 Free PMC article.
-
Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands.Cancer Immunol Immunother. 2016 Jun;65(6):689-700. doi: 10.1007/s00262-016-1828-3. Epub 2016 Mar 31. Cancer Immunol Immunother. 2016. PMID: 27034235 Free PMC article.
-
Immunotherapy for lung cancer: for whom the bell tolls?Tumour Biol. 2015 Mar;36(3):1411-22. doi: 10.1007/s13277-015-3285-6. Epub 2015 Mar 4. Tumour Biol. 2015. PMID: 25736929 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
